Innopharma, Inc. Sustainability Profile
Innopharma, Inc., a leading name in the pharmaceutical and biotechnology sectors, is headquartered in the United States. Founded in 2008, the company has established itself as a key player in the development of innovative drug delivery systems and advanced pharmaceutical formulations. With a strong focus on enhancing patient outcomes, Innopharma operates primarily in North America and Europe, delivering cutting-edge solutions that address complex healthcare challenges. The company’s core offerings include specialised drug formulation services and analytical testing, which are distinguished by their commitment to quality and regulatory compliance. Innopharma's notable achievements include successful collaborations with major pharmaceutical firms, positioning it as a trusted partner in the industry. With a reputation for excellence and a dedication to innovation, Innopharma continues to shape the future of pharmaceutical development.
DitchCarbon Score
How does Innopharma, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Innopharma, Inc.'s score of 84 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Innopharma, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. However, the company is part of a corporate family relationship with Pfizer Inc., from which it inherits climate commitments and initiatives. Innopharma's climate strategy is influenced by Pfizer Inc.'s sustainability efforts, which include various initiatives aimed at reducing carbon emissions. These initiatives are part of broader commitments to environmental responsibility, although specific reduction targets for Innopharma have not been detailed. As a current subsidiary of Pfizer Inc., Innopharma aligns with the climate pledges and targets set by its parent company, which are cascaded down through the corporate structure. This includes participation in initiatives such as the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and RE100, all of which are spearheaded by Pfizer Inc. While Innopharma does not have its own emissions data or specific reduction targets, it is positioned within a framework that prioritises sustainability and climate action, reflecting the commitments of its parent organisation.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 964,846,000 | - | - | - | - | - | - | - | 000,000,000 | - | - | - | 000,000,000 |
| Scope 2 | 883,814,000 | - | - | - | - | - | - | - | 000,000,000 | - | - | - | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 000,000,000 | 0,000,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 0,000,000,000 |
How Carbon Intensive is Innopharma, Inc.'s Industry?
How Carbon Intensive is Innopharma, Inc.'s Location?
Innopharma, Inc.'s Scope 3 Categories Breakdown
Innopharma, Inc.'s Scope 3 emissions, which increased significantly last year and increased by approximately 821% since 2019, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 77% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 79% of Scope 3 emissions.
Top Scope 3 Categories
Innopharma, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Innopharma, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
